We conducted 2 sequential studies of donor leukocyte infusion (DLI) in 26 patients with
chronic myeloid leukemia in hematologic relapse after unmodified allogeneic bone marrow …

Donor lymphocyte infusion (DLI) is used to prevent or treat haematological malignancies
relapse after allogeneic stem cell transplantation (allo-SCT). Recombinant human …

We studied the graft-versus-leukaemia (GVL) effect in 185 patients with haematological
malignancies who underwent unrelated donor haematopoietic stem cell transplantation …

Allogeneic bone marrow transplantation (BMT) is the only curative therapy for chronic
myeloid leukemia (CML), but relapse occurs in approximately 10% of patients transplanted …

PURPOSE To review the current state of knowledge regarding the management of leukemic
relapse after allogeneic bone marrow transplantation (BMT). PATIENTS AND METHODS …

Eight patients who had hematologic relapse of chronic myelogenous leukemia (CML) after
undergoing allogeneic bone marrow transplantation (BMT) were treated with leukocyte …

Discusses who may benefit from donor leucocyte infusions after allogeneic stem cell
transplantation. Toxicity of donor leucocyte infusions; Time delay between the infusion of …

Donor lymphocyte infusion (DLI) using unstimulated leukapheresis is one of the most
effective treatment strategies for patients with hematological malignancies; its graft-versus …

Allogeneic bone marrow transplantation (BMT) is the treatment of choice for hematologic
malignancies resistant to conventional chemotherapy and for patients who are at high risk …

To assess the consequence of second BMT (BMT2) for leukemia relapse after allogeneic
BMT, we analyzed the clinical course of 66 recipients who were treated by BMT2 in Japan …